Hansa Biopharma Schedules Extraordinary General Meeting
Hansa Biopharma AB (publ) has announced an Extraordinary General Meeting to be held on September 22, 2026, in Lund, Sweden. The meeting will address matters stipulated by the company's articles of association.
Lund, Sweden – Hansa Biopharma AB (publ) has issued a notice for an Extraordinary General Meeting (EGM) of its shareholders. The meeting is scheduled for September 22, 2026, commencing at 15:00 CEST at the company's offices located at Scheelevägen 22, SE-223 63 Lund.
Registration for attendees will begin at 14:30 CEST. Shareholders eligible to participate must be recorded in the company's share register on the record date and must submit a participation notice in advance. The company did not specify the agenda items for the EGM in its initial announcement.
Typically, EGMs are convened to discuss significant corporate decisions, such as changes to the board of directors, amendments to the company's articles of association, or other material matters requiring shareholder approval outside of the regular annual meeting schedule.
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on addressing unmet medical needs in rare and life-threatening diseases. The company's pipeline is driven by its proprietary enzyme technology platform, which has the potential to target a range of immunological conditions. Hansa Biopharma's shares are listed on Nasdaq Stockholm.